Meeting
2019 Genitourinary Cancers Symposium
Association of the commensal urinary microbiome with response to Bacillus Calmette-Guérin (BCG) immunotherapy in nonmuscle invasive bladder cancer.
Authors
Randy F. Sweis
The University of Chicago, Chicago, IL
Randy F. Sweis , Shay Golan , Nimrod Barashi , Elle Hill , Ciro Andolfi , Ryan P. Werntz , Jeffrey Bloodworth , Gary D. Steinberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 423)
DOI
10.1200/JCO.2019.37.7_suppl.423
Abstract #
423
Poster Bd #
H14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.
First Author: Michiel Simon Van Der Heijden
Poster
2023 ASCO Genitourinary Cancers Symposium
Comparison of urine cell-free DNA with blood-based screening for detection of bladder cancer.
First Author: Tyler F. Stewart
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
First Author: Edward M. Uchio
Poster
2022 ASCO Genitourinary Cancers Symposium
Atezolizumab (atezo) with or without Bacille Calmette-Guérin (BCG) in patients (pts) with high-risk nonmuscle-invasive bladder cancer (NMIBC): Results from a phase Ib/II study.
First Author: Noah M. Hahn